In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide Gastric inhibitory polypeptide (GIP), human | Synthetic analog Retatrutide | |
|---|---|---|---|
| Identity | |||
| Kind | Natural peptide | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | No results yet | 380 | |
| Evidence level | No study results | Has results from studies in people | |
| Safety | |||
| Safety results | No safety results | 61 (61 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | None registered | 34 · 11 active | |
From the regulatory data of each peptide.
The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
No outcome group has study results for two or more of these peptides.
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Retatrutide differs from Gastric inhibitory polypeptide (GIP) at 15 positions and in 1 end segment.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
No registered trial that tests Gastric inhibitory polypeptide (GIP), human found in ClinicalTrials.gov.
Top 3 of 34 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Eli Lilly and Company10,000 participants30 Apr 2024 to est. Feb 2029
Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Eli Lilly and Company4,500 participants15 Oct 2025 to est. Aug 2032
Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company2,335 participants10 Jul 2023 to 30 Apr 2026
Obesity · Overweight · Osteoarthritis, Knee · Obstructive Sleep Apnea